PFE darling and pretty chart.

Looking to break $4 for good.
Consolidating at $3.90's.
Hope it's not going to be double top fail.
Time will tell.

LVTX..............................https://stockcharts.com/h-sc/ui?s=LVTX&p=W&b=5&g=0&id=p86431144783

Excellent week.
Hopefully $4 next week.

Beautiful chart. Breakout past $3.30 to. $3.35.
Lots of cash.
Looking for at least $5 soon. Maybe more.
JMO.

LVTX 10Q due 3/22

Nice bounce back above $3.
Would love another run to $3.25.
I think this has good chance to move to $4 sooner or later. Lots of cash.
JMO

Crazy stock dropped on earnings news which means nothing IMO.
Typical sell on news. Stock will need to regroup before it can retest $3.
They have huge amounts of cash and good partners.
I am holding through this sell off.

Interesting. Trying to breakout.
Needs news.

Nice chart. They have cash to last until 2026.
Needs to breakout past $3 with volume.
Tried several times but failed.

LVTX.........................................https://stockcharts.com/h-sc/ui?s=LVTX&p=W&b=5&g=0&id=p86431144783

LVTX.................................................https://stockcharts.com/h-sc/ui?s=LVTX&p=W&b=5&g=0&id=p86431144783

LVTX new 52 week high

Nice pump today sold some shares made a bundle ….weeeeeeeeeee

Insider and institutional ownership here are pretty big numbers. With the Merck partnership this should be heading North when the dip buying resolves..... This will soon be a battle ground between $3 and $4!

I hit this for a few more shares at 1.96 in Pre-market. I read some further and like the Merck Deal and that fact that they have the Balance Sheet Strength to partner with them!!!! Let's see how long I have to hold on to this, for it to Double from here!!!!

LVTX: I think we ALL eventually learned today this THIS ONE is a dud!!! (DAMN-IT!!!)

WHAT DID I TEACH YOU LAST TIME : KNEEL AND OBEY YOUR MASTER !!

WATCH AND LEARN LOSER

LVTX: And there she goes!! (That MERCK name can do things, ya know.)

LVTX: The heck with those "SXTC-like", Chinese BAD-Fortune-Cookie routines!! Check-out the LVTX 'Bollinger-Curves' on MY cute 'Scanners'!! (See below!!)

"I suddenly feel a Short-SQUEEZE of sorts comin' on!! Can ya all help-me-out a little bit, Fellas??!!"
/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

OK SO NOW YOU'RE A MIND READER !! SIMPLY AMAZING !!
SO KEEP INVESTING IN THESE MICKEY MOUSE STOCKS, MAYBE ONE DAY THE LOTTO
IS IN YOUR FUTURE. ONE MORE REMINDER : ALWAYS LISSSSSSSSSSSSSSSSSSSSTEN TO YOUR MASTER !!

you own nothing...go back to work....you're lunch break is almost over

THE MARKET SELL OFF I COMING VERY SOON. EVEN THOUGH I'M LONG, GOT PLENTY OF PROTECTION.

crown what happen to the market crash you keep telling people...stick to the trolling son...fake traders never lose!!!

YOU MEAN THE MASTER TRADER OF ALL TIMES !!
OK SENIOR; VERY SIMPLE REALLY; STICK WITH MSFT, NVDA, AMZN GOOG, AND META.
DON'T OVRERTHINK IT.

coming from one of the great ihub traders i should listen to you...what are you buying these days big fella

SELL !!

LVTX...COME ON YOU CAN DO IT

LVTX NEXT BIOP BEAST DAY TRADER

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Bought some Dip..... May pick up some more if the Morning Open get's a pullback...... Good one for a Move up into weekend!!!!!

LVTX 2.74= $$

$LVTX 2.44 I BOUGHT 1.92'S, YOU IN?

Cash Position The company has 28.7 months of cash left based on quarterly cash burn of -$9.62M and estimated current cash of $92.1M.
https://dilutiontracker.com/app/search/LVTX

Very nice find! Thank you so much! ")

$LVTX 1.89 NEWS Collaboration with Merck & Co $MRK

https://www.globenewswire.com/news-release/2024/01/25/2816550/0/en/LAVA-Therapeutics-Announces-Collaboration-with-Merck-Co-Inc-Rahway-NJ-USA-to-Evaluate-LAVA-1207-in-Combination-with-KEYTRUDA.html

LVTX under $2

LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies.
In May 2020, LAVA entered into a research collaboration and license agreement with Janssen for the discovery and development of novel bispecific antibody-based gamma delta T cell engagers for the treatment of cancer. The agreement was facilitated by Johnson & Johnson Innovation.
LAVA is also eligible to receive potential development, regulatory and commercialization milestone payments and tiered royalties.
UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a company in the clinical stage of immuno-oncology, is dedicated to advancing its unique Gammabody™ platform, which involves the development of bispecific gamma-delta T cell engagers. Today, LAVA Therapeutics announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has chosen a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings. This decision was made within the framework of a previously announced collaboration agreement, which aims to discover and create innovative bispecific antibodies targeting gamma-delta T cells as a potential treatment for cancer. Upon such election, Janssen is responsible for the future clinical development, manufacture, and commercialization of the candidate at Janssen’s sole cost and expense. The agreement was facilitated by Johnson & Johnson Innovation.

“We are very pleased that Janssen selected a lead candidate for its licensed target under the research collaboration initiated in 2020 to move towards clinical studies,” said Stephen Hurly, president and chief executive officer of LAVA Therapeutics. “LAVA is pioneering the development of gamma-delta bispecific antibodies to treat cancer through our proprietary Gammabody platform and deep bispecific expertise as we look to advance novel therapies for patients.”

About LAVA TherapeuticsLAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering V?9Vd2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. A Phase 1/2a dose escalation clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in the US and EU (NCT05369000). A Phase 1/2a dose escalation clinical study to evaluate LAVA-051, for the treatment of multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia, is also enrolling patients in the EU and US (NCT04887259). The Company has a license agreement with Seagen for the development of SGN-EGFRd2 (LAVA-1223). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

LAVA’s Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, including with respect to the Company’s anticipated growth and clinical development plans including the timing and results of clinical trials. Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential,” “suggests” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include but are not limited to statements about the expected safety profile of our product candidates, preclinical data, clinical development and scope of clinical trials, including the availability of data therefrom, the potential use of our product candidates to treat various tumor targets, any payments to us under our license agreements with third parties and our expected cash runway. Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of our research and development programs and preclinical and clinical trials, the risk that results obtained in clinical trials to date may not be indicative of results obtained in ongoing or future trials, our ability to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our initial programs to develop additional product candidates using our Gammabody™ platform, and the failure of LAVA’s collaborators to support or advance collaborations or our product candidates. The COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing, and supply chain or impairing employee productivity. In addition, there may be adverse effects on our business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including deteriorating market conditions due to investor concerns regarding inflation and hostilities between Russia and Ukraine, and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures. These and other risks are described in greater detail under the caption “Risk Factors” and included in LAVA’s filings with the Securities and Exchange Commission. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACTS

Investor Relations
ir@lavatherapeutics.com

Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com

https://www.globenewswire.com/newsroom/ti?nf=ODg1MDk5OSM1NjI3MzEzIzIyMDY3OTE=

https://stockcharts.com/h-sc/ui?s=lvtx&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/lvtx/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/lvtx/opinion

https://www.barchart.com/stocks/quotes/lvtx/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);ADX(14);SMA(50);SMACD(12,26,9);RSI(14,100);ACCUM;STOSL(14,3)&sym=CNNA&grid=1&height=500&studyheight=100

Always dumping even with good news. MYbe someday I’ll make my money back. Next year maybe

The company is dumping shares on the bid.
Looking bad again today.
I'm going to pass on this one.
I'll drop by again if the company stops dumping shares.

Huge run-up of 99% at one point it was up 205%. Will it continue? I wonder.

I've been waiting for this to break, all day long. But the company is too interest in financing (dumping shares).

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
September 26 2022 - 08:00AM
Business Wire
Alert
Print
Share On Facebook
– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate V?9Vd2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors –

– LAVA to Receive Upfront Payment of $50 Million, With Potential for Milestones of up to Approximately $650 Million and Royalties–

– Seagen also has an Option to Nominate up to Two Additional Tumor Targets for Bispecifics using LAVA’s Proprietary Gammabody™ Platform –

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced preclinical asset that utilizes LAVA’s proprietary Gammabody™ technology to target epidermal growth factor receptor (EGFR)-expressing solid tumors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005204/en/

Under the terms of the agreement, Seagen will receive an exclusive global license for LAVA-1223 and pay LAVA $50 million upfront; up to approximately $650 million in potential development, regulatory and commercial milestones; and royalties ranging from the single digits to the mid-teens on future sales. The agreement also provides Seagen with the opportunity to exclusively negotiate rights to apply LAVA's proprietary Gammabody™ platform on up to two additional tumor targets.

“Seagen is committed to driving innovation to improve the lives of people with cancer, and this agreement represents the company’s entry into a novel class of therapeutics that are designed to overcome the challenges of standard T cell engagers by leveraging the activity of a distinct T cell subset,” said Roger Dansey, M.D., interim CEO and Chief Medical Officer, Seagen. “This exclusive license from LAVA provides Seagen with the opportunity to harness its expertise in developing first-in-class targeted cancer therapies, along with the company’s global development and commercialization capabilities.”

LAVA-1223 employs a targeted approach that is designed to amplify natural tumor recognition by directing gamma delta T cells to the EGFR+ tumor to kill target cells and trigger immune activation while minimizing impact to normal antigen-expressing tissue. Activating the adaptive immune system with this approach has the potential to provide durable immune responses with the possibility of enhancing patient survival.

“LAVA is pioneering the development of gamma delta bispecific antibodies to treat cancer, and we are pleased to work with Seagen in this pursuit. The combination of LAVA’s proprietary Gammabody platform and deep bispecific expertise, with Seagen’s leadership in developing targeted therapies for cancer and commercialization infrastructure, makes this an ideal partnership to advance novel therapies for patients,” said Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics. “This agreement enables LAVA to further validate its platform in a second solid tumor product candidate, bringing us closer toward our goal of generating effective Gammabody medicines for cancer patients. We look forward to working with Seagen to develop potential next generation cancer treatments.”

About LAVA-1223

LAVA-1223 is a potential first-in-class therapy designed specifically to target and activate V?9Vd2 (gamma delta) T cells in the presence of epidermal growth factor receptor (EGFR)-expressing tumor cells. EGFR is a well-validated target that is over-expressed in multiple solid tumor types including colorectal cancer, lung cancer and head and neck cancer.

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and